ClinicalTrials.gg
WithdrawnNCT03242967TRILOGYUpdated Nov 5, 2018

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

A Phase 3 interventional study of Vadadustat and Darbepoetin alfa in Anemia and Dialysis-Dependent Chronic Kidney Disease, sponsored by Akebia Therapeutics. Withdrawn at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-11-05.

Sponsored by Akebia Therapeutics · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Revised study design.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
25th of 27
0 · median 60
Started
2017
with 2 others
Phase 3
14 of 27
none open now
Registered
15th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 25th largest by enrollment, is one of 3 that started in 2017, is one of 14 in phase 3, and was the 15th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

This is a Phase 3 Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

03

Conditions studied

  • Anemia
  • Dialysis-Dependent Chronic Kidney Disease

Browse trials for

Keywords

  • Anemia
  • hemoglobin
  • darbepoetin alfa
  • TIW
  • hypoxia-inducible factor prolyl-hydroxylase inhibitor
  • HIF-PHI
  • AKB-6548
  • vadadustat
  • renal
  • hypoxia-inducible factor
  • HIF
  • dialysis-dependent chronic kidney disease
  • CKD
  • DD-CKD
  • kidney
  • erythropoiesis stimulating agent
  • ESA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female subjects ≥18 years of age
  • Receiving chronic maintenance in-center hemodialysis (3 times per week) for end-stage kidney disease
  • Currently maintained on ESA therapy
  • Mean screening between 8.0 and 11.0 g/dL (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss
  • Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic , myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia
  • Red blood cell transfusion within 4 weeks prior to or during screening
  • Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vadadustat

    Oral tablet

    Drug: Vadadustat

  • Active comparator
    Darbepoetin alfa

    subcutaneous or intravenous

    Drug: Darbepoetin alfa

Interventions

06

What researchers measure

Primary outcomes

  1. Mean change in Hb between baseline and the primary evaluation period

    Mean change in hemoglobin will be evaluated

    Time frame: Baseline visit, Week 36

Secondary outcomes

  1. Mean change in Hb between baseline and the secondary evaluation period

    Mean change in hemoglobin will be evaluated

    Time frame: Baseline visit, Week 52

  2. Proportion of subjects with mean Hb within the target range during the primary evaluation period

    Hemoglobin values within the target range will be evaluated

    Time frame: Baseline visit, Week 36

  3. Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Adverse Events (AEs) and Serious Adverse Events (SAEs) will be evaluated

    Time frame: 52 weeks

07

Study locations

1 site
  • Research Site
    Northridge, California 91324, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2017
First posted
Aug 8, 2017
StartEst.
Aug 2017
Primary completionActual
Feb 12, 2018
CompletionActual
Feb 12, 2018
Last update
Nov 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03242967
Responsible party
Sponsor
First posted
Aug 8, 2017
Start date
Aug 2017 (estimated)
Primary completion
Feb 12, 2018
Completion
Feb 12, 2018
Last update
Nov 5, 2018

Study contacts

Akebia Therapeutics
study director · Sponsor GmbH

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion